In late 2023, the FDA aggressively updated its bulk drug substances list
(CSE: SURE) (OTCQB: SURNF), (Profile) through its subsidiary GlucaPharm Inc., is advancing a differentiated next-generation GLP-1 platform centered on GEP-44, a novel triple agonist peptide designed to improve efficacy, tolerability and delivery flexibility in one of the fastest-growing pharmaceutical markets in history
Neutralizing Scalp Inflammation and Oxidative Stress Chronic scalp inflammation is often the hidden culprit behind accelerated hair thinning
The truth is that science often moves more slowly than headlines
doi: 10.1210/jc.2013-3607 50 HybyeCThornMBhmB
Overall, the uniquely rapid need for neutrophil effector functions, such as NETosis, phagocytosis and degranulation, to be mobilized quickly in the innate immune response necessitates brisk production of NADPH, which is chiefly controlled by the PPP rate-limiting activity of G6PD